I seldom comment on fellow bloggers’ posts, but Kevin Noonan’s recent article in PatentDocs deserves some attention. He basically has taken the recent PTO Guidelines to their “logical” extreme. The Guidelines contain an example that suggests that the Myriad ruling should be applied to “natural products” other than isolated pieces of genomic DNA. In Kevin’s [...]
The post USPTO Guidelines Blur “Natural” And “Novel” Products appeared first on Biotechnology Patent Law Blog | Patents4Life by Warren Woessner.